Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Kodiak Sciences Inc. (KOD : NSDQ)
 
 • Company Description   
Kodiak Sciences Inc. operates as a clinical stage biopharmaceutical company. It specializes in novel therapeutics to treat chronic and retinal diseases. The company's product candidates consists of KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and Uveitis, KSI-201 for treatment resistant wet AMD and KSI-401 for dry AMD which are in clinical stage. Kodiak Sciences Inc. is based in CA, United States.

Number of Employees: 93

 
 • Price / Volume Information   
Yesterday's Closing Price: $5.70 Daily Weekly Monthly
20 Day Moving Average: 896,377 shares
Shares Outstanding: 51.95 (millions)
Market Capitalization: $296.14 (millions)
Beta: 1.98
52 Week High: $131.97
52 Week Low: $4.90
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -11.90% -3.47%
12 Week -89.16% -88.24%
Year To Date -93.28% -92.00%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1200 PAGE MILL ROAD
-
PALO ALTO,CA 94304
USA
ph: 650-281-0850
fax: -
ir@kodiak.com http://www.kodiak.com
 
 • General Corporate Information   
Officers
Victor Perlroth - Chief Executive Officer and Chairman
John Borgeson - Chief Financial Officer
Felix J. Baker - Director
Charles Bancroft - Director
Bassil I. Dahiyat - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 50015M109
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/08/22
Share - Related Items
Shares Outstanding: 51.95
Most Recent Split Date: (:1)
Beta: 1.98
Market Capitalization: $296.14 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.44 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-6.06 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/08/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.50
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -86.73%
vs. Previous Quarter: -2.23%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -45.15
12/31/21 - -35.71
09/30/21 - -27.65
ROA
03/31/22 - -33.66
12/31/21 - -27.43
09/30/21 - -21.74
Current Ratio
03/31/22 - 8.94
12/31/21 - 11.36
09/30/21 - 14.81
Quick Ratio
03/31/22 - 8.94
12/31/21 - 11.36
09/30/21 - 14.81
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 11.50
12/31/21 - 12.83
09/30/21 - 14.04
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©